Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma

NCT07878689 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT07878689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07878689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2029
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)